Inspire Medical Systems (NYSE: INSP), a medical technology company focused on minimally invasive treatments for obstructive sleep apnea (OSA), appointed seasoned medical device executive Michael H. Carrel to its Board of Directors, effective July 20. Chairman and CEO Tim Herbert said the company looks forward to his guidance as it advances Inspire therapy.
Carrel has served as President, Chief Executive Officer and director of AtriCure (NASDAQ: ATRC) since November 2012. Under his leadership, AtriCure’s revenue grew from $82 million in 2013 to $535 million in 2025, treating more than one million patients. He previously chaired the board of Axonics from 2019 to 2024, through its sale to Boston Scientific. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School. He cited Inspire’s fifth-generation device, product pipeline and growing evidence of long-term cardiovascular benefits as reasons he believes the company is well positioned to expand access for OSA patients.
Loading…
Loading translation…
Positive
- Board strengthened with experienced operator Michael H. Carrel joins as director, bringing long-tenured CEO and board experience at medical device companies.
- AtriCure revenue track record grew from $82 million in 2013 to $535 million in 2025 under Carrel’s leadership, alongside treatment of over one million patients.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Board appointment adds proven medical device leadership
MINNEAPOLIS, July 27, 2026 (GLOBE NEWSWIRE) — Inspire Medical Systems, Inc. (NYSE: INSP), a medical technology company focused on innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the appointment of seasoned medical device executive Michael H. Carrel to its Board of Directors effective July 20.
“We are pleased to welcome Mr. Carrel to our Board of Directors,” said Tim Herbert, Chairman and Chief Executive Officer of Inspire Medical Systems. “Mike brings extensive executive leadership, board and medical device experience, including a strong track record of developing and commercializing minimally invasive therapies, and we look forward to his guidance as we continue advancing Inspire therapy for the many patients affected by OSA.”
Mr. Carrel has served as President, Chief Executive Officer, and a director of AtriCure, Inc. (NASDAQ: ATRC), an innovative cardiac device company, since November 2012. Under Mr. Carrel’s leadership, AtriCure has advanced a robust pipeline of novel products for the treatment of atrial fibrillation, left atrial appendage management and pain management. During his tenure, AtriCure has grown from
Previously, Mr. Carrel served as Chairman of the Board of Directors of Axonics, Inc. from 2019 through 2024, until its sale to Boston Scientific Corporation. Mr. Carrel holds a B.S. in Accounting from Pennsylvania State University and an M.B.A. from The Wharton School of the University of Pennsylvania.
“I am excited to join Inspire at this important stage in the Company’s growth,” said Mr. Carrel. “With the recent launch of the fifth-generation Inspire device, a compelling product pipeline and a growing body of evidence demonstrating the long-term benefits of Inspire therapy, particularly in cardiovascular health, I believe the Company is well positioned to continue expanding access to care for patients with OSA.”
About Inspire Medical Systems
Inspire is a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first FDA-, EU MDR- and PDMA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.
For additional information about Inspire, please visit www.inspiresleep.com.
Investor and Media Contact
Ezgi Yagci
Vice President, Investor Relations
ezgiyagci@inspiresleep.com
617-549-2443
FAQ
Who is Michael H. Carrel and what is his new role at Inspire Medical Systems (NYSE: INSP)?
Michael H. Carrel is a seasoned medical device executive appointed to Inspire Medical Systems’ Board of Directors. According to Inspire Medical Systems, he brings extensive CEO, board and commercial experience from AtriCure and Axonics, supporting the company’s focus on minimally invasive therapies for obstructive sleep apnea.
When did Inspire Medical Systems appoint Michael H. Carrel to its Board of Directors?
Inspire Medical Systems appointed Michael H. Carrel to its Board of Directors effective July 20. According to Inspire Medical Systems, the announcement was made on July 27, 2026, highlighting the addition of his executive and medical device leadership at a key stage of the company’s growth.
What experience from AtriCure does Michael H. Carrel bring to Inspire Medical Systems (INSP)?
Michael H. Carrel has led AtriCure as President, CEO and director since November 2012. According to Inspire Medical Systems, AtriCure’s revenue increased from $82 million in 2013 to $535 million in 2025 under his leadership, while its products helped treat more than one million patients.
How might Michael H. Carrel’s appointment impact Inspire Medical Systems’ obstructive sleep apnea strategy?
Michael H. Carrel is expected to provide strategic guidance rather than operational leadership. According to Inspire Medical Systems, management values his track record in developing and commercializing minimally invasive therapies as the company advances Inspire therapy and expands access for patients with obstructive sleep apnea.
What recent products and evidence did Michael H. Carrel highlight when joining Inspire Medical Systems (INSP)?
Michael H. Carrel referenced the recent launch of Inspire’s fifth-generation device and a compelling product pipeline. According to Inspire Medical Systems, he also noted a growing body of evidence supporting the long-term benefits of Inspire therapy, particularly in cardiovascular health for patients with obstructive sleep apnea.
What prior board experience does Michael H. Carrel have before joining Inspire Medical Systems’ board?
Before joining Inspire Medical Systems’ board, Michael H. Carrel served as Chairman of the Board of Axonics from 2019 through 2024. According to Inspire Medical Systems, his tenure at Axonics included the period leading up to its sale to Boston Scientific, adding significant transaction experience.